Ajay Royan Acquires 23,000 Shares of Fractyl Health (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ajay Royan acquired 23,000 shares of Fractyl Health stock in a transaction dated Friday, June 12th. The shares were bought at an average price of $0.85 per share, with a total value of $19,550.00. Following the transaction, the director directly owned 40,901 shares in the company, valued at approximately $34,765.85. The trade was a 128.48% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Fractyl Health Trading Down 8.7%

Shares of Fractyl Health stock opened at $0.78 on Wednesday. The company has a fifty day simple moving average of $0.71 and a 200-day simple moving average of $1.06. Fractyl Health, Inc. has a 12-month low of $0.38 and a 12-month high of $2.45. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. The stock has a market cap of $123.11 million, a price-to-earnings ratio of -0.60 and a beta of 2.34.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.23. On average, equities analysts forecast that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Analysts Set New Price Targets

GUTS has been the subject of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $5.40.

Hedge Funds Weigh In On Fractyl Health

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of Fractyl Health during the second quarter worth approximately $31,000. FNY Investment Advisers LLC purchased a new position in shares of Fractyl Health during the third quarter worth approximately $31,000. Jump Financial LLC purchased a new position in shares of Fractyl Health during the fourth quarter worth approximately $57,000. Scientech Research LLC purchased a new position in shares of Fractyl Health during the third quarter worth approximately $49,000. Finally, Prelude Capital Management LLC purchased a new position in shares of Fractyl Health during the third quarter worth approximately $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.